LONDON, July 2, 2018 /PRNewswire/ -- Report Scope
The scope of this study includes core synthetic biology products (synthetic genes, BioBrick parts, delivery plasmids, chassis organisms, synthetic cells, cell-free systems and production systems), enabling technologies (DNA sequencing, DNA synthesis and assembly, gene editing, bioinformatics and specialty media) and enabled technologies (healthcare, industrial chemicals, consumer products, food and beverages, and agriculture) that are already commercialized or are forecast to be commercialized within the next five years.
Download the full report: https://www.reportbuyer.com/product/2212006
We analyze key synthetic biology technologies and products to determine present and future market status and forecasted growth from 2017 through 2022. We also discuss strategic alliances, industry structures, competitive dynamics, patents, and market-driving forces.
BCC Research examines the synthetic biology industry by market segment, including the following segments: DNA sequencing, DNA synthesis, gene editing, synthetic biology foundries, software, and the following enabled products sectors: agriculture, consumer products, cosmetics/skin care, food and beverages, healthcare, and industrial chemicals.
The role of key strategic alliances and acquisitions from 2016 through 2017 is discussed. Emerging markets including synthetic genes, synthetic biology-enabled drugs and vaccines, genome-edited crops, and chassis organisms, as well as metabolically engineered factories for producing synthetic fuels and specialty chemicals are analyzed, and more than 185 companies in these fields are highlighted.
Report Includes
- An overview of the global markets for synthetic biology
- Analyses of global market trends, with data from 2016, 2017, and projections of compound annual growth rates (CAGRs) through 2022
- Coverage of core synthetic biology products: synthetic genes, other DNA parts, chassis organisms, synthetic cells
- Coverage of enabling technologies: DNA sequencing, oligonucleotides, specialty media, bioinformatics
- Coverage of enabled technologies: biofuels, specialty chemicals, diagnostics, pharmaceuticals, agriculture
- Analysis of the synthetic biology industry structure, competitors, and intellectual property landscape
- Assessments of the products and technologies most commercially viable now and in the near future
- Company profiles of major players in the market, including Illumina, Inc, New England Biolabs, Precision Biosciences, Royal Dsm Nv, Sgi-Dna Inc., Synthetic and Genomics, Inc
Summary
DNA is an industrial and medical wonder material of the 21st Century: This polymer is the core material of synthetic biology.Synthetic biology encompasses all aspects of DNA, including its reading, writing, and editing.
For example, DNA editing tools like CRISPR or zinc finger nucleases are changing synthetic biology and driving market applications and growth.
These tools enable both development of novel cell lines and synthesis of important proteins. The combination of gene-editing tools and host engineering platforms enables development of new proteins more effectively.
Innovations in CRISPR gene editing tools promise to transform this field, including nano-particle delivery of CRISPR systems (MIT) and non-Cas9 gene editing.
In November 2017 Sangamo, a gene editing company, announced treatment of the first patient to undergo in-vivo gene editing for Hunters Syndrome.This was the first time that a patient received therapy to edit DNA of cells directly inside of the body.
This marked a new era in gene editing because the edited DNA is integrated permanently into the patient's DNA. Sangamo's in vivo gene editing product candidates have received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration.
This report examines the dynamic synthetic-biology industry, including its technologies and global markets, and notes the leading companies in each of the market segments.
The synthetic-biology industry consists of three main sets of technologies and products: enabling, core and enabled.Enabling technologies and products are the engine that drives the development of the synthetic biology industry.
Core products and technologies—standardized DNA parts, synthetic genes and chassis organisms—are the key tools by which cellular factories and systems produce enabled products.
Products enabled by synthetic biology tools—pharmaceuticals, chemicals, biofuels and agricultural— have large downstream market potential.Synthetic biology technologies add value in each of these downstream industries.
For example, synthetic biology has simplified the commercialization pathway for genome-edited crops in the agriculture industry and enhanced the availability, quality control and testing of novel synthetic genes in the drug development industry.
Download the full report: https://www.reportbuyer.com/product/2212006
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +1 (718) 213 4904
Website: www.reportbuyer.com
SOURCE ReportBuyer
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article